Boehringer Ingelheim

The views and opinions expressed in these recordings are those of the authors and do not necessarily reflect the views of Boehringer Ingelheim (Pty) Ltd ("Boehringer Ingelheim") and Boehringer Ingelheim assumes no liability for the interpretation and/or use of the information contained in this recording, nor does it offer a warranty of any kind, either expressed or implied.

Boehringer Ingelheim its group companies take the protection of your Personal Data seriously. Boehringer Ingelheim only transfers Personal Data to third parties according to applicable law, especially when you have expressly given your consent, when required to deliver services that you ordered, or when we engage service providers that use Personal Data on our behalf and according to our instructions. Read the BI Privacy statement here. 

Pharmacovigilance: Health Care physicians can report any adverse event (lack of efficacy, off label use, over dose with or without AE, medication error with or without AE, drug abuse/misuse, drug interaction, occupational exposure, pregnancy / lactation exposure and therapeutical response increase and/or unexpected benefit) occurring during or after administration of a marketed Boehringer Ingelheim product they become aware of either by written or verbal means by contacting Boehringer Ingelheim’s’ responsible Pharmacovigilance unit using the below contact details: 

Email: [email protected]

Approval number: PC-ZA-100358